Future studies should aim to capture the immunomodulatory effects in more immunogenic breast cancer subtypes, such as high-risk HR-positive/HER2-negative, HER2-positive, and triple-negative breast carcinomas. This evidence concerns the gene ERBB2 and breast cancer.